- The outcome of repeat sentinel lymph node biopsy (rSLNB) has no prognostic effect in patients with breast cancer with ipsilateral breast tumor recurrence (IBTR).
Why this matters
- rSLNB is not useful as a staging tool or for developing treatment plans for IBTR.
- Prospective cohort of 515 patients with breast cancer with IBTR in 36 Dutch hospitals participating in SNARB.
- Outcome of rSLNB was tumor-positive, tumor-negative, or unsuccessful.
- A positive outcome was defined as lymph node containing either macrometastases (>2.0 mm) and/or micrometastases (>0.2 mm and/or >200 cells).
- Primary outcome was outcome of rSLNB in relation to distant recurrence-free survival (RFS).
- Funding: None disclosed.
- rSLNB was tumor-negative in 44.7%, tumor-positive in 8.9%, and unsuccessful in 46.4%.
- 22.3% of patients had developed a recurrence after a median follow-up of 5.1 years.
- The overall 5-year distant RFS rate was 84.2% (95% CI, 80.7%-87.7%).
- No association was found between outcome of rSLNB and distant RFS (P=.682).
- Poor distant RFS was associated with:
- An interval of
- Triple-negative IBTR (HR, 1.82; P =.045).
- Absence of adjuvant chemotherapy after IBTR (P =.010).
- Observational design.